Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors

Curr Opin Investig Drugs. 2002 Apr;3(4):627-33.

Abstract

In recent years the importance of epigenetic changes in carcinogenesis has been unfolding. It is now clear that the fifth base of the genome, methylcytosine, plays a critical role in the control of gene expression during normal development and carcinogenesis. Efforts to decrease methylation in neoplasias as a therapeutic strategy have been productive in hematologic malignancies but disappointing in solid tumors. The following is a review of the clinical experience with the agents 5-azacytidine and 5-aza-2'-deoxycytidine in solid malignancies and a discussion of the difficulties encountered.

Publication types

  • Review

MeSH terms

  • Antimetabolites, Antineoplastic / adverse effects
  • Antimetabolites, Antineoplastic / pharmacology*
  • Azacitidine / analogs & derivatives*
  • Azacitidine / pharmacology*
  • Azacitidine / therapeutic use
  • Clinical Trials as Topic
  • DNA Methylation
  • Decitabine
  • Hematologic Agents / adverse effects
  • Hematologic Agents / pharmacology*
  • Hematologic Diseases / drug therapy
  • Humans
  • Neoplasms / drug therapy

Substances

  • Antimetabolites, Antineoplastic
  • Hematologic Agents
  • Decitabine
  • Azacitidine